Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
FDA reporter Lizzy Lawrence joins 'The Readout LOUD' to dissect Dr. Makary's departure from his role, the policies that may endure, and the implicatio...
Xeber.world
clinical trials
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Biogen’s experimental Alzheimer’s drug diranersen reduced tau levels in early-stage patients and slowed cognitive decline in a Phase 2 trial. Meanwhil...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen announced mixed results from a Phase 2 Alzheimer’s trial testing diranersen (BIIB080), a tau-targeting therapy. The drug reduced tau levels in...
Regenxbio’s Duchenne Gene Therapy Shows Success in Trial, FDA Submission Next
Regenxbio announced positive results from its Duchenne muscular dystrophy gene therapy trial, achieving high levels of a critical muscle protein. The...
FDA Commissioner Marty Makary Resigns Amid Leadership Controversy; Eli Lilly Weight Loss Drug Trial Results Released
FDA Commissioner Marty Makary resigns after months of internal scrutiny, with Kyle Diamantas stepping in as acting commissioner. Meanwhile, Eli Lilly'...
New Study Warns: Common Drug May Reduce Gene Therapy Effectiveness in Dravet Syndrome Patients
A new trial by Encoded Therapeutics reveals that sirolimus, a drug used to prevent immune rejection in gene therapy, may also diminish treatment effec...
FDA Commissioner Marty Makary's Sudden Exit Leaves Agency in Turmoil Amid Leadership Vacuum
Marty Makary's abrupt departure from the FDA removes a key Trump administration lightning rod but fails to resolve deep organizational instability. Wi...
Right to Try Law Fails Patients Despite FDA Rejection of RP1 Melanoma Therapy
The FDA’s rejection of RP1, an experimental melanoma treatment, highlights the limitations of the 2018 Right to Try Act. Despite its promise to grant...
Capsida Biotherapeutics Unable to Determine Cause of Child’s Death in Gene Therapy Trial
Capsida Biotherapeutics remains uncertain about the cause of a child’s death in a gene therapy trial conducted last September. The investigation has s...
Low-Dose Endoxifen Shows Promise in Reducing Breast Density with Fewer Side Effects Than Tamoxifen
A clinical trial published in the Journal of the National Cancer Institute found that low doses of (Z)-endoxifen significantly reduced mammographic br...
FDA Proposes Removing 'Gender' References in Regulations; Louisiana Challenges Abortion Pill Access
The FDA proposes removing 'gender' from its regulations, sparking concerns about research impacts on gender minorities. Meanwhile, Louisiana urges the...
Sanofi Withdraws Teplizumab from FDA Fast-Track Review Amid Leadership Dispute
Sanofi has requested the FDA remove its type 1 diabetes drug teplizumab from a fast-track review program after a dispute between agency staff and acti...
FDA Reverses Rejection of Ebvallo for Rare Blood Cancer After Clinical Trial Review
Pierre Fabre Pharmaceuticals and Atara Biotherapeutics announced that the FDA has reconsidered its rejection of Ebvallo, a therapy for a rare blood ca...
Analysts Overlook Lilly’s Liver Concerns Too Quickly, Experts Question Risk Assessment
Vertex Pharma halts early-stage mRNA cystic fibrosis therapy VX-522 due to tolerability issues. Cytokinetics’ Myqorzo meets dual efficacy goals in gen...
RFK Jr. Targets Antidepressants, J&J Advances IBD Drug: Key Pharma Updates You Need to Know
U.S. Health Secretary Robert F. Kennedy Jr. announced new initiatives to reduce reliance on widely prescribed antidepressants like Zoloft and Prozac....
Johnson & Johnson Advances IBD Therapy JNJ-4804 Despite Phase 2b Trial Miss
Johnson & Johnson’s experimental IBD therapy JNJ-4804, combining Tremfya and Simponi, failed to meet its primary endpoint in Phase 2b trials for ulcer...
Latus Bio Secures $42M to Launch Huntington’s and Batten Disease Gene Therapy Trials
Latus Bio, a gene therapy startup, has raised $42 million to advance two clinical trials in 2024, including treatments for Batten disease and Huntingt...
Psychedelic Research Boom Excludes People of Color, Critics Warn
President Trump’s executive order accelerates psychedelic research access, but advocates warn the movement risks leaving behind communities of color....
FDA Accelerates Clinical Trials with Real-Time Data, Pfizer Extends Vyndamax Patent Until 2031
The FDA is piloting real-time clinical trial data reviews with AstraZeneca and Amgen, while Pfizer settles patent disputes to extend Vyndamax protecti...
FDA Launches AI-Powered Initiative to Accelerate Clinical Trials with Real-Time Data Review
The FDA has announced a new effort to enhance clinical trial efficiency by reviewing real-time data from trials conducted by AstraZeneca and Amgen. Th...
FDA Commissioner Advocates for Real-Time Clinical Trials to Accelerate Drug Development
The average drug takes a decade to reach the market due to inefficiencies in clinical trials. FDA Commissioner Robert Califf highlights that 45% of th...
Boehringer’s Obesity Drug Achieves 16.6% Weight Loss in Trial; Further Data Pending
Boehringer’s investigational obesity drug demonstrated a 16.6% weight loss in a clinical trial, outperforming many existing treatments. However, addit...
Erasca’s RAS-Targeting Pill Shows Strong Early Results in Pancreatic and Lung Cancer Trials
Erasca’s RAS-targeting pill, ERAS-0015, reduced tumors in 40% of advanced pancreatic cancer patients and 62% of advanced non-small cell lung cancer pa...
Astellas Revives XLMTM Gene Therapy Trial After Patient Deaths: Key Biotech Updates
Astellas is reentering clinical trials for its next-generation XLMTM gene therapy following patient deaths. Eli Lilly acquires Ajax Therapeutics for u...
Oruka’s ORKA-001 Shows 63% Complete Skin Clearance in Plaque Psoriasis Trial
Oruka Therapeutics reported that 63% of plaque psoriasis patients achieved complete skin clearance in a mid-stage trial of its long-acting injectable...
FDA Fast-Tracks Psilocybin and Methylone for Depression and PTSD Treatment
Six days after President Trump signed an executive order to expedite psychedelic drug reviews, the FDA issued national priority vouchers for psilocybi...
Can Erasca Challenge Revolution Medicines as the Next Big Player in Pancreatic Cancer Treatment?
Erasca, valued at nearly $7 billion, is racing to prove its pan-RAS inhibitor ERAS-0015 could rival Revolution Medicines in pancreatic cancer treatmen...
Medicare Postpones Obesity Drug Coverage Pilot Amid Biotech Updates on RevMed, Roche, and Kyverna CAR-T Therapy
Medicare has delayed a pilot program to cover obesity drugs for seniors, reversing a key healthcare initiative from the Trump administration. This com...
Moderna Advances Bird Flu Vaccine Study, Reduces U.S. Operations
Moderna is continuing its research into a bird flu vaccine but has scaled back U.S.-based operations. The company is focusing efforts on global health...
Roche’s MS Drug Fenebrutinib Advances to Regulators After Positive Trial Data, But Safety Concerns Persist
Roche has presented new trial data for its experimental multiple sclerosis drug fenebrutinib, aiming to secure regulatory approval. While the drug sho...